* Cue Biopharma Inc CUE.OQ CUE.O is expected to show a
fall in
quarterly revenue when it reports results on November 14.
* The Boston Massachusetts-based company is expected to
report a
81.6% decrease in revenue to $440.33 thousand from $2.4 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Cue Biopharma Inc
is for
a loss of 38 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Cue
Biopharma Inc
is $12.5, above its last closing price of $3.14.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.43 -0.42 -0.37 Beat 12.6
Mar. 31 2022 -0.43 -0.43 -0.44 Missed -2.9
Dec. 31 2021 -0.45 -0.38 -0.25 Beat 35.1
Sep. 30 2021 -0.38 -0.39 -0.41 Missed -5.1
Jun. -0.41 -0.42 -0.33 Beat 20.7
30 2021
Mar. 31 2021 -0.38 -0.38 -0.41 Missed -8.5
Dec. 31 2020 -0.35 -0.35 -0.36 Missed -2.9
Sep. 30 2020 -0.39 -0.38 -0.34 Beat 11.5
This summary was machine generated November 11 at 23:26 GMT.
All figures in US dollars unless otherwise stated